Navigation Links
NeurogesX to Present at Piper Jaffray Health Care Conference
Date:11/24/2009

SAN MATEO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 21st Annual Piper Jaffray Health Care Conference, to be held December 1-2, 2009 at The New York Palace Hotel in New York, New York.

Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions during the presentations and to participate in one-on-one meetings with investors attending the conferences.

Event: 21st Annual Piper Jaffray Health Care Conference

Date: Wednesday, December 2, 2009

Time: 11:00 a.m. ET

Place: The New York Palace Hotel, NYC (Holmes 1: 4th Floor)

Both presentations will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcasts will be archived for 90 days.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza(TM) (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. NeurogesX expects to launch Qutenza in United States in the first half of 2010 for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.

The Company's second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.

The Company's early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the safety and efficacy of Qutenza(TM); the timing of launch of Qutenza; and development activities for NGX-1998 and other product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: any regulatory approvals which are received may be limited to certain indications; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; difficulties or delays in the launch and commercialization of Qutenza; and the outcomes of any submissions to the FDA for NeurogesX' products and product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.


NeurogesX, Inc.                  The Ruth Group
Stephen Ghiglieri                Sara Pellegrino (investors)
Chief Financial Officer          (646) 536-7002
(650) 358-3310                   spellegrino@theruthgroup.com

                                 Jason Rando (media)
                                 (646) 536-7025
                                 jrando@theruthgroup.com

SOURCE NeurogesX, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX Reports Third Quarter 2009 Results
2. NeurogesX to Present at Two November Conferences
3. NeurogesX to Present at UBS Global Life Sciences Conference
4. NeurogesX to Present at Upcoming Fall Conferences
5. NeurogesX Appoints New Board Director and Audit Committee Chairman
6. NeurogesX Reports Second Quarter 2009 Results
7. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
8. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
9. NeurogesX Added to Russell 3000 Index
10. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
11. NeurogesX to Present at Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Research and Markets has announced the addition of ... to their offering. ... , This report describes ... such as proteomics and metabolomics. Molecular diagnostics technologies are used for ... biomarker. Currently the most important applications of biomarkers are ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... resume cervical and lumbar disc production, company President, Jake Lubinski will be traveling ... implanting the AxioMed disc in Cologne and Karlsruhe to discuss the benefits of ...
(Date:12/5/2016)... , Dec. 5, 2016  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, announced ... the company as Chief Financial Officer (CFO), effective ... with 20 years of experience in financial management ... biotech and software companies. Most recently, Ms. Bovenizer ...
(Date:12/5/2016)... GRAND RAPIDS, Mich. , Dec. 5, 2016 NxGen MDx ... "By bringing the test in house, we,ve been able to improve ... costs down for patients," says Alan Mack , CEO of NxGen ... , , ... increase in test volume has led to more job opportunities at the ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):